Related Experiment Video
Updated: Jun 20, 2026
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Treating nonalcoholic fatty liver disease
Nahum Méndez-Sánchez1, Marco Arrese, Daniel Zamora-Valdés
1Unidad de Hígado, Departamento de Investigación Biomédica, Fundación Clínica Médica Sur, México D.F., México. nmendez@medicasur.org.mx
Summary
Nonalcoholic fatty liver disease (NAFLD) is a progressive liver condition. Current treatments focus on lifestyle changes, but new therapies are emerging from research to improve patient outcomes.
Area of Science:
- Hepatology
- Gastroenterology
- Internal Medicine
Background:
- Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum from simple steatosis to progressive nonalcoholic steatohepatitis (NASH).
- NASH can lead to liver fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma.
- Current NAFLD management relies on lifestyle modifications and metabolic disorder control.
Purpose of the Study:
- To review the current literature on the treatment of nonalcoholic fatty liver disease.
- To provide an overview of existing and emerging therapeutic strategies for NAFLD.
Main Methods:
- Comprehensive literature search of scientific databases.
- Analysis of published studies on NAFLD treatments.
- Synthesis of findings on current and novel therapeutic approaches.
Main Results:
- Current NAFLD therapy is limited to lifestyle interventions and management of comorbidities.
- Emerging treatments are being developed from basic research for clinical application.
- The review covers a range of therapeutic strategies under investigation.
Conclusions:
- Effective treatment options for NAFLD are limited, highlighting the need for new interventions.
- Ongoing research shows promise for novel therapies to address the spectrum of NAFLD.
- A shift towards more targeted and effective treatments for NAFLD is anticipated.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...